Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cara Therapeutics, Inc. (CARA)

12.43   0.11 (0.89%) 12-07 16:00
Open: 12.25 Pre. Close: 12.32
High: 12.54 Low: 12.24
Volume: 256,733 Market Cap: 668(M)

Technical analysis

as of: 2022-12-07 4:20:58 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 14.96     One year: 17.47
Support: Support1: 10.18    Support2: 8.56
Resistance: Resistance1: 12.81    Resistance2: 14.96
Pivot: 11.53
Moving Average: MA(5): 12.39     MA(20): 11.34
MA(100): 10.28     MA(250): 10.46
MACD: MACD(12,26): 0.6     Signal(9): 0.5
Stochastic oscillator: %K(14,3): 81.8     %D(3): 87.6
RSI: RSI(14): 69.2
52-week: High: 13.96  Low: 7.4
Average Vol(K): 3-Month: 342 (K)  10-Days: 247 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CARA ] has closed below upper band by 16.1%. Bollinger Bands are 17.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.55 - 12.61 12.61 - 12.67
Low: 12.09 - 12.16 12.16 - 12.22
Close: 12.33 - 12.43 12.43 - 12.53

Company Description

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Headline News

Wed, 07 Dec 2022
Foot Locker comms head Cara Tocci leaves to launch consultancy - PR Week

Wed, 07 Dec 2022
Big Fish: The Artful Work of Cara Ober, Founding Editor of BmoreArt - Baltimore Fishbowl

Tue, 06 Dec 2022
Fitness Mompreneur Cara Loren Talks Balance, Motivation, & Focusing on the Good - CafeMom

Fri, 02 Dec 2022
A Chatty Cara Delevingne Explores Love and Lust in Fresh, Engaging Magazine Show ‘Planet Sex’: TV Review - Variety

Thu, 01 Dec 2022
Dallas' Cara Mia Theatre revives play that saved it from collapse - The Dallas Morning News

Thu, 01 Dec 2022
In Memoriam: Christine McVie, Irene Cara and more - Goldmine Magazine

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 54 (M)
Shares Float 45 (M)
% Held by Insiders 16.1 (%)
% Held by Institutions 66.8 (%)
Shares Short 6,270 (K)
Shares Short P.Month 6,620 (K)

Stock Financials

EPS -1.8
EPS Est Next Qtl -0.38
EPS Est This Year -1.78
EPS Est Next Year -1.87
Book Value (p.s.) 3.44
Profit Margin (%) -224.6
Operating Margin (%) -227.7
Return on Assets (ttm) -25.6
Return on Equity (ttm) -45.2
Qtrly Rev. Growth -46.8
Gross Profit (p.s.) -1.12
Sales Per Share 0.73
EBITDA (p.s.) -1.67
Qtrly Earnings Growth 0
Operating Cash Flow -56 (M)
Levered Free Cash Flow -22 (M)

Stock Valuations

PE Ratio -6.91
PEG Ratio -0.1
Price to Book value 3.61
Price to Sales 16.93
Price to Cash Flow -11.83

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.